- Life Science
- Flow cytometry
- Digital pathology
- QC & Online Services
- Document Centre
- Knowledge Centre
- Clinic & Laboratory
Select your local website
Earlier recognition. Better survival rates. Synergy in expertise.
Over 400,000 of new cases of colorectal cancer are diagnosed in Europe each year. Yet early recognition, individualising cancer therapy, and using less invasive diagnostics are leading to improved prognoses and greater quality of life. Identifying the cancer early on is especially important for therapeutic success. Screening – both symptomatic and especially large-scale – is essential.
Everything we offer is designed to help clinicians, laboratories and physicians that adress screening, diagnosis and therapy of colorectal cancer disease.
The quantitative FOB Gold FIT (Faecal immunological testing) screening test delivers more reliable results than the standard qualitative test. Extremely flexible, it can be adapted to screening programmes of any size and to laboratories with all throughputs.
When determining therapy, often whether to give chemotherapy or not, the stage of the cancer is decisive. Sensitive, standardised lymph node diagnostics and the resulting nodal status are essential here. OSNA delivers the sensitivity and standardisation required and reduces false-negatives compared to classic histopathology.
Using antibodies alongside chemotherapy has improved the overall survival of CRC patients.1 But clinicians must test stringently which patients are eligible. The OncoBEAMTM RAS CRC test uses a blood sample instead of tumour tissue and overcomes the limitations of tissue biopsies like sample availability, turnaround time and tumour heterogeneity.
- Lee J.J. et al.(2016): Options for Second-Line Treatment in Metastatic Colorectal Cancer. Clinical Advances in Hematology & Oncology, 14(1):46-54.